| Cited in | Search | Type: | Non-patent literature | Publication information: | [XY] ZHANG SHANNON S ET AL: "Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer", LUNG CANCER: TARGETS AND THERAPY, DOVE MEDICAL PRESS, vol. 12, 1 January 2021 (2021-01-01), pages 115 - 122, XP009536735, ISSN: 1179-2728, DOI: 10.2147/LCTT.S334623 | DOI: | http://dx.doi.org/10.2147/LCTT.S334623 | Type: | Non-patent literature | Publication information: | [Y] HONG DAVID S. ET AL: "KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors", vol. 383, no. 13, 24 September 2020 (2020-09-24), US, pages 1207 - 1217, XP055911440, ISSN: 0028-4793, Retrieved from the Internet DOI: 10.1056/NEJMoa1917239 | DOI: | http://dx.doi.org/10.1056/NEJMoa1917239 | Type: | Non-patent literature | Publication information: | [Y] "Report from the ESMO Virtual Congress, 19th -21st September 2020", MEMO - MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, vol. 13, no. Suppl 5, 19 September 2020 (2020-09-19), pages 111 - 132, XP037305270, ISSN: 1865-5041, DOI: 10.1007/S12254-020-00666-1 | DOI: | http://dx.doi.org/10.1007/s12254-020-00666-1 | Type: | Non-patent literature | Publication information: | [Y] UPRETY DIPESH ET AL: "KRAS: From undruggable to a druggable Cancer Target", CANCER TREATMENT REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 89, 15 July 2020 (2020-07-15), XP086252172, ISSN: 0305-7372, [retrieved on 20200715], DOI: 10.1016/J.CTRV.2020.102070 | DOI: | http://dx.doi.org/10.1016/j.ctrv.2020.102070 | Cited in | by applicant | Type: | Patent literature | Publication No.: | US10519146
| Type: | Patent literature | Publication No.: | US2020369662
| Type: | Non-patent literature | Publication information: | BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, 1977, pages 1 - 19 | Type: | Non-patent literature | Publication information: | FERNANDEZ-MEDARDE ASANTOS E: "Ras in cancer and developmental diseases", GENES CANCER., vol. 2, no. 3, 2011, pages 344 - 358, XP055459147, DOI: 10.1177/1947601911411084 | DOI: | http://dx.doi.org/10.1177/1947601911411084 | Type: | Non-patent literature | Publication information: | PRIOR IALEWIS PDMATTOS C: "A comprehensive survey of Ras mutations in cancer", CANCER RES., vol. 72, no. 10, 2012, pages 2457 - 2467, XP055117242, DOI: 10.1158/0008-5472.CAN-11-2612 | DOI: | http://dx.doi.org/10.1158/0008-5472.CAN-11-2612 | Type: | Non-patent literature | Publication information: | "Pharmaceutical Dosage Forms", vol. 1-3, 1992, MARCEL DEKKER | Type: | Non-patent literature | Publication information: | ARTHUR H. KIBBE: "Handbook of Pharmaceutical Excipients", 2000, AMERICAN PHARMACEUTICAL ASSOCIATION | Type: | Non-patent literature | Publication information: | ARBOUR KCJORDAN EKIM HR ET AL.: "Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer", CLIN CANCER RES., vol. 24, no. 2, 2018, pages 334 - 340 | Type: | Non-patent literature | Publication information: | "American Association for Cancer Research (AACR) Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium", CANCER DISCOV, vol. 7, no. 8, 2017, pages 818 - 831 | Type: | Non-patent literature | Publication information: | JONES RPSUTTON PAEVANS JP ET AL.: "Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer", BR J CANCER., vol. 116, no. 7, 2017, pages 923 - 929 | Type: | Non-patent literature | Publication information: | AN JYAN MYU N ET AL.: "Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation", J CLIN ONCOL., vol. 38, 2020, pages 9033 - 9033 | Type: | Non-patent literature | Publication information: | BARBACID M., RAS GENES. ANNUAL REV BIOCHEM., vol. 56, 1987, pages 779 - 827 | Type: | Non-patent literature | Publication information: | "Atezolizumab Prescribing Information", April 2021 | Type: | Non-patent literature | Publication information: | BIERNACKA ATSONGALIS PDPETERSON JD ET AL.: "The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma", CANCER GENET., vol. 209, no. 5, 2016, pages 195 - 198 | Type: | Non-patent literature | Publication information: | BLUMENTHAL, SWKARURI SWZHAN H ET AL.: "Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses", J CLIN ONCOL., vol. 33, no. 9, 20 March 2015 (2015-03-20), pages 1008 - 1014 | Type: | Non-patent literature | Publication information: | BORGHAEI HPAZ-ARES LHORN L ET AL.: "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N ENGLJ MED., vol. 373, no. 17, 2015, pages 1627 - 1639, XP055667804, DOI: 10.1056/NEJMoa1507643 | DOI: | http://dx.doi.org/10.1056/NEJMoa1507643 | Type: | Non-patent literature | Publication information: | CANON, JREX, KSAIKI, AY ET AL.: "The clinical KRAS(G12C) inhibitor AMG 510 drives antitumour immunity", NATURE, vol. 575, 2019, pages 217 - 223 | Type: | Non-patent literature | Publication information: | CLARKE JWANG XREADY N: "Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?", TRANSLLUNG CANCER RES., vol. 4, no. 6, December 2015 (2015-12-01), pages 804 - 808 | Type: | Non-patent literature | Publication information: | CULLY MDOWNWARD J.: "SnapShot: Ras Signaling", CELL, vol. 133, 2008, pages 1292 | Type: | Non-patent literature | Publication information: | DAVIS AAPATEL VG: "The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors", J IMMUNOTHER CANCER, vol. 7, no. 1, 2019, pages 278, XP055702333, DOI: 10.1186/s40425-019-0768-9 | DOI: | http://dx.doi.org/10.1186/s40425-019-0768-9 | Type: | Non-patent literature | Publication information: | EISENHAUER EATHERASSE PBOGAERTS J ET AL.: "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1", EUR J CANCER., vol. 45, 2009, pages 228 - 247, XP025841550, DOI: 10.1016/j.ejca.2008.10.026 | DOI: | http://dx.doi.org/10.1016/j.ejca.2008.10.026 | Type: | Non-patent literature | Publication information: | ETTINGER DSWOOD DEAGGARWAL C ET AL.: "NCCN Guidelines Insights: Non-small Cell Lung Cancer, Version 1.2020", J NATL COMPR CANC NETW., vol. 17, no. 12, 2019, pages 1464 - 1472 | Type: | Non-patent literature | Publication information: | FUSCO MJWEST HWALKO CM: "Tumor Mutation Burden and Cancer Treatment", JAMA ONCOL., vol. 7, no. 2, 2021, pages 316, XP009551380, DOI: 10.1001/jamaoncol.2020.6371 | DOI: | http://dx.doi.org/10.1001/jamaoncol.2020.6371 | Type: | Non-patent literature | Publication information: | GAINOR JFVARGHESE AMOU SH ET AL.: "ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer", CLIN CANCER RES., vol. 19, no. 15, 2013, pages 4273 - 4281 | Type: | Non-patent literature | Publication information: | GLOBOCAN 2018 - LUNG, August 2019 (2019-08-01), Retrieved from the Internet | Type: | Non-patent literature | Publication information: | GOEMAN FDE NICOLA FSCALERA S ET AL.: "Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma", J THORAC ONCOL., vol. 14, no. 11, 2019, pages 1924 - 1934 | Type: | Non-patent literature | Publication information: | GRIDELLI CCATALONO PJMEROPOL NJ ET AL.: "Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced non-small cell lung cancer. The AvaALL randomized clinical trial", JAMA ONC., vol. 4, no. 12, 2018, pages e183486 | Type: | Non-patent literature | Publication information: | HERBST RSBAAS PKIN DW ET AL.: "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.", LANCET., vol. 387, 2016, pages 1540 - 1550, XP029496410, DOI: 10.1016/S0140-6736(15)01281-7 | DOI: | http://dx.doi.org/10.1016/S0140-6736(15)01281-7 | Type: | Non-patent literature | Publication information: | HERBST RSO'NEILL, FEHRENBACHER L ET AL.: "Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer", J CLIN ONCOL., vol. 25, no. 30, 2007, pages 4743 - 4750 | Type: | Non-patent literature | Publication information: | HONG DSFAKIH MGSTRICKLER JH ET AL.: "KRASG12c Inhibition with Sotorasib in Advanced Solid Tumors", N ENGLJ MED., vol. 383, 2020, pages 1207 - 1217, XP055911440, DOI: 10.1056/NEJMoa1917239 | DOI: | http://dx.doi.org/10.1056/NEJMoa1917239 | Type: | Non-patent literature | Publication information: | JEONG YHELLYER JASTEHR H ET AL.: "Role of KEAPI/NFE2L2 mutations in the chemotherapeutic response of patients with non-small cell lung cancer", CLIN CANCER RES., vol. 26, no. 1, 2020, pages 274 - 281 | Type: | Non-patent literature | Publication information: | MARTORELL MPHUERTA MCOMPAN QUILIS A ET AL.: "Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients", CLIN LUNG CANCER., vol. 18, no. 6, November 2017 (2017-11-01), pages e395 - e402 | Type: | Non-patent literature | Publication information: | MCCORMICK F.: "K-Ras protein as a drug target", JMOL MED (BERL, vol. 94, no. 3, 2016, pages 253 - 258, XP035801349, DOI: 10.1007/s00109-016-1382-7 | DOI: | http://dx.doi.org/10.1007/s00109-016-1382-7 | Type: | Non-patent literature | Publication information: | MCCORMICK F.: "Progress in targeting RAS with small molecule drugs", BIOCHEM J., vol. 476, 2019, pages 365 - 374 | Type: | Non-patent literature | Publication information: | OKEN MCREECH RTORMEY D ET AL.: "Toxicity and response criteria of the Eastern Cooperative Oncology Group", AM J CLIN ONCOL., vol. 5, 1982, pages 649 - 655, XP055910491 | Type: | Non-patent literature | Publication information: | OSTREM JMPETERS USOS MLWELLS JASHOKAT KM: "K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions", NATURE, vol. 503, 2013, pages 548 - 551 | Type: | Non-patent literature | Publication information: | PAVAN AZULATO ECALVETTI L ET AL.: "Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): impact of STK11 and TP53 mutations on outcome", J CLIN ONCOL., vol. 38, no. 15, 2020, pages 3046 - 3046 | Type: | Non-patent literature | Publication information: | "Prembrolizumab Prescribing Information", November 2020 | Type: | Non-patent literature | Publication information: | PLANCHARD SPOPAT KKERR S ET AL.: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", ANN ONCOL., vol. 29, 2018, pages iv192 - iv237 | Type: | Non-patent literature | Publication information: | RICCIUTI BARBOUR KCLIN JJ ET AL.: "Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status", J CLIN ONCOL., vol. 38, no. 15, 2020, pages e15113 - e15113 | Type: | Non-patent literature | Publication information: | RITTMEYER ABARLESI FWATERKAMP D ET AL.: "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial", LANCET, vol. 380, 2017, pages 255 - 265 | Type: | Non-patent literature | Publication information: | ROMAN MBARAIBAR ILOPEZ I ET AL.: "KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target", MOL CANCER., vol. 17, no. 1, 2018, pages 33, XP093150362, DOI: 10.1186/s12943-018-0789-x | DOI: | http://dx.doi.org/10.1186/s12943-018-0789-x | Type: | Non-patent literature | Publication information: | SCHEFFLER MIHLE MAHEIN R ET AL.: "K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways", J THORAC ONCOL., vol. 14, no. 4, 2019, pages 606 - 616 | Type: | Non-patent literature | Publication information: | SIMANSHU DKNISSLEY DVMCCORMICK F: "RAS proteins and their regulators in human disease", CELL, vol. 170, 2017, pages 17 - 33, XP085117958, DOI: 10.1016/j.cell.2017.06.009 | DOI: | http://dx.doi.org/10.1016/j.cell.2017.06.009 | Type: | Non-patent literature | Publication information: | SOLIS LMBEHRENS CDONG W ET AL.: "Nrf2 and KEAP1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features", CLIN CANCER RES., vol. 16, no. 14, 2010, pages 3743 - 3753, XP055227526, DOI: 10.1158/1078-0432.CCR-09-3352 | DOI: | http://dx.doi.org/10.1158/1078-0432.CCR-09-3352 | Type: | Non-patent literature | Publication information: | TAMIYA YZENKE YMATSUMOTO S ET AL.: "Therapeutic impact of mutation subtypes and concomitant STK 11 mutations in KRAS-mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan", J CLIN ONCOL., vol. 38, 2020, pages 9589 - 9589 | Type: | Non-patent literature | Publication information: | TIAN YWU KLIU Q ET AL.: "Modification of platinum sensitivity by KEAP 1/NRF2 signals in non-small cell lung cancer", J HEMATOL ONCOL., vol. 9, no. 1, 2016, pages 83, XP055531697, DOI: 10.1186/s13045-016-0311-0 | DOI: | http://dx.doi.org/10.1186/s13045-016-0311-0 | Type: | Non-patent literature | Publication information: | UBA RRAEZ LEDUMAIS K ET AL.: "Serine/threonine kinase 11 (STK11) mutations and immunotherapy resistance in patients with non-small cell lung cancer", J CLIN ONCOL., vol. 38, 2020, pages e 15055 - e 15055 | Type: | Non-patent literature | Publication information: | VAN CUTSEM ECERVANTES AB. NORDLINGER BARNOLD D: "ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", ANN ONCOL., vol. 25, 2014, pages iiil - iii9 | Type: | Non-patent literature | Publication information: | WORLD HEALTH ORGANIZATION. 2018 STATISTICS, October 2020 (2020-10-01), Retrieved from the Internet |
